Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 113Colorectal Neoplasms 73Stomach Neoplasms 48Pancreatic Neoplasms 45Rectal Neoplasms 40Neoplasms 29Neoplasm Metastasis 29Colonic Neoplasms 18Esophageal Neoplasms 16Triple Negative Breast Neoplasms 13Adenocarcinoma 11Parkinson Disease 4, Autosomal Dominant Lewy Body 10Gallbladder Neoplasms 9Bile Duct Neoplasms 8Brain Neoplasms 7Adenocarcinoma Of Esophagus 7Liver Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Cholangiocarcinoma 5Breast Neoplasms, Male 5Somatostatinoma 4Head and Neck Neoplasms 4Carcinoma, Hepatocellular 4Biliary Tract Neoplasms 4Gastrointestinal Neoplasms 3Gastrinoma 3Esophageal Squamous Cell Carcinoma 3Carcinoma, Squamous Cell 3Carcinoma, Renal Cell 3Solid Tumor 2

Interventions

ganitumab 2conatumumab 1cixutumumab 1Paclitaxel 1Lapatinib 1Carboplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Insulin-Like Growth Factor I, Resistance To × Capecitabine × Clear all
NCT00684983 2020-03-24

Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer

National Cancer Institute (NCI)

Phase 2 Completed
64 enrolled 13 charts
Breast

Insulin-Like Growth Factor I, Resistance To, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡